Current Approaches to Vaccine Development of Streptococcus pyogenes
- PMID: 36479760
- Bookshelf ID: NBK587096
Current Approaches to Vaccine Development of Streptococcus pyogenes
© The University of Oklahoma Health Sciences Center.
Sections
- Introduction and Historical Perspective
-
S. pyogenes phylogeny and comparative genomic analysis ofS. pyogenes antigens -
S. pyogenes vaccine development strategies - M protein-based vaccine candidates
- Non-M protein-based vaccine candidates
-
Animal models to evaluate vaccine efficacy against
S. pyogenes infections -
Adjuvants in
S. pyogenes vaccine development -
S. pyogenes human challenge model and correlates of protection -
Human clinical trials of
S. pyogenes vaccines - Conclusion
- Acknowledgements
- References
References
-
- Andrejko K., Whittles L. K., Lewnard J. A. Health-economic value of vaccination against Group A Streptococcus in the United States. Clinical Infectious Diseases 2021 June 30; - PubMed
-
- Auzanneau F.-I., Borrelli S., Pinto B. M. Synthesis and immunological activity of an oligosaccharide-conjugate as a vaccine candidate against Group A Streptococcus. Bioorganic and Medicinal Chemistry Letters. 2013 November 15;23(22):6038–6042. - PubMed
-
- Azuar A., Li Z., Shibu M. A., Zhao L., Luo Y., Shalash A. O., Skwarczynski M. Poly(hydrophobic amino acid)-based self-adjuvanting nanoparticles for Group A Streptococcus vaccine delivery. Journal of Medicinal Chemistry. 2021 March 11;64(5):2648–2658. - PubMed
-
- Baay M. F., Richie T. L., Neels P., S. C. Human challenge trials in vaccine development, Rockville, MD, USA, September 28-30, 2017. Biologicals. 2019 September;61:85–94. - PubMed
Publication types
LinkOut - more resources
Full Text Sources